A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

NCT02834247 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient efficacy of drug; no safety concern

Conditions

Triple-Negative Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Head and Neck Carcinoma, Squamous Cell
Advanced Solid Tumors

Interventions

DRUG: TAK-659
DRUG: Nivolumab

Sponsor

Calithera Biosciences, Inc